- Email: [email protected]
P-6-24 Efect of insulin treatment on high density lipoprotein composition and lcat activity in diabetic patients
P-6-24 EFECT OF INSULIN TREATMENT ON HIGH DENSITY LIPOPROTEIN COMPOSITION AND LCAT ACTIVITY IN DIABETIC PATIENTS. T.Iizuka, N.Fukuzawa, K.Kimura and Y.Akanuma The Institute for Diabetes Care and Research, Asahi Life Foundation, Tokyo, Japan Plasma lipids, lipoproteins, apolipoproteins and lecithin: cholesterol acyltransferase(LCAT) activity were mesured in 91 diabetic patients(53 males and 38 females) before and after the admission of approximately 23 days. The treatment was insulin in addition to diet treatment and exercise. Compared to the pre-admission, the following results were obtained at the time of discharge, l)body weight, fasting blood glucose, triglyceride, total cholesterol, HDL, apolipoproteins(A-I, A-II, B, C-II, C-III, E) and insulin doses were significantly decreased, 2)the plasma level of HDL2-cholesterol did not change, however HDL3-cholesterol significantly decreased, resulting in a significant increase of HDL2-cholesterol/HDL3-cholesterol ratio, 3)apolipoproteins A-I/A-II ratio was significantly increased from 4.9 to 5.3, 4)LCAT activities were significantly decreased from 790 to 637(nmol/ml.hour). In conclusion, insulin treatment during admission made a significant change in the composition of HDL as well as LCAT activity suggesting an antiatherogenic pattern of HDL metabolism.
P-6-25 INCREASED FASTING TRIGLYCERIDE LIPASE ACTIVITY IN NORMOLIPIDEMIC NIDDM PATIENTS H.Mukaida, K.Ninomiya, H.Saito and Y.Maruhama Department of Medicine I, School of Medicine, lwate Medical University, Morioka, Japan This study was performed to examine fasting (non-stimulated) and postheparin plasma triglyceride lipase activity (TLA) in diabetics. Although TLA, in general, has been measured only in plasma after i.v. heparin, a highly sensitive method for TLA assay was developed, in which plasma was applied to Heparin-Sepharose CL-6B column and eluted with 0.3M NaCI, 0.002 M barbital buffer, containing 6mg/ml Na heparin. TLA was assayed using 14Ctriolein substrate with serum as activator. Whereas heparin-releasable TLA tended to be lower in normolipidemic diabetics (n=14) than in controls (n=8), the fasting TLA was found to be significantly increased in the diabetics as compared with the controls (20±7 vs. 13±5 n mol FFA/ml/hr, M±SD). Apoprotein C subgroups in very low density lipoprotein (VLDL) showed no abnormalities in the diabetics and the reductions of VLDL triglyceride after i.v. heparin were almost equal between the diabetics and controls. Thus, some unknown factor seems to increase fasting plasma TLA in NIDDM patients.
$60
P-6-25 INCREASED FASTING TRIGLYCERIDE LIPASE ACTIVITY IN NORMOLIPIDEMIC NIDDM PATIENTS H.Mukaida, K.Ninomiya, H.Saito and Y.Maruhama Department of Medicine I, School of Medicine, lwate Medical University, Morioka, Japan This study was performed to examine fasting (non-stimulated) and postheparin plasma triglyceride lipase activity (TLA) in diabetics. Although TLA, in general, has been measured only in plasma after i.v. heparin, a highly sensitive method for TLA assay was developed, in which plasma was applied to Heparin-Sepharose CL-6B column and eluted with 0.3M NaCI, 0.002 M barbital buffer, containing 6mg/ml Na heparin. TLA was assayed using 14Ctriolein substrate with serum as activator. Whereas heparin-releasable TLA tended to be lower in normolipidemic diabetics (n=14) than in controls (n=8), the fasting TLA was found to be significantly increased in the diabetics as compared with the controls (20±7 vs. 13±5 n mol FFA/ml/hr, M±SD). Apoprotein C subgroups in very low density lipoprotein (VLDL) showed no abnormalities in the diabetics and the reductions of VLDL triglyceride after i.v. heparin were almost equal between the diabetics and controls. Thus, some unknown factor seems to increase fasting plasma TLA in NIDDM patients.
$60